Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ACADEMIA
ACADEMIA
- “No Major Differences” Between 4 AD Treatments; More Evidence Needed: Prof. Hanyu
October 20, 2011
- Positive Results for Avastin in Japanese PII Trial in Recurrent GBM: JNS
October 13, 2011
- Nexium Significantly Reduces Incidence of Acid Reflux Compared to Omepral: Study Report
October 10, 2011
- Prof. Uchiyama Stresses Need for Caution with Prazaxa Even at Low Dose
October 10, 2011
- JGS Opposes OTC Switch for 8 Ethical Drugs on Ground of Patients’ High Ages
October 7, 2011
- HRT is Cost Efficient Treatment: JSMWH
October 6, 2011
- Humira Top Choice Among Biopharmaceuticals for Psoriasis Treatment: Prof. Nakagawa
October 6, 2011
- Patients Need to Be Warned of Risk of Relapse if They Discontinue Antidepressants: Prof. Iwata
October 6, 2011
- Med. Institutions Prefer GE Anticancer Drugs from Companies with Better Support Systems: Ms Matsui of NCC Hospital East
October 3, 2011
- Decision to Prescribe Prazaxa Should Be Left to Specialists for Now: JCS Press Seminar
September 30, 2011
- 95% of Patients Favor Comprehensive Agreements to Use Tissue for Research: NCC
September 26, 2011
- JASSO to Announce New Diagnostic Guidelines for Obesity
September 26, 2011
- Insurers Favor Incentives to Pharmacies to Promote Use of Generics: Seminar
September 26, 2011
- Regulatory Science Society Holds 1st Scientific Convention
September 19, 2011
- NCGM Hospital Removes Actos from List of Recommended Drugs in Diabetes Manual
September 14, 2011
- Clinical Positioning Needs to Be Clarified for Nexavar, Sutent: Prof. Naito of Kyushu Univ.
September 12, 2011
- Intensive Therapy with Rosuvastatin Effective at Inhibiting Progression of IMT: JART Study
September 12, 2011
- Apixaban Superior to Warfarin, Risk of Major Bleeding Down 30%: ESC
September 12, 2011
- 42 Nat’l Univ. Hospitals Share Drug Price Information to Reduce Purchase Costs
September 12, 2011
- NCC Aims to Become World’s Leading Early Clinical Development Center
September 12, 2011
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…